Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus SOX for conversion therapy in unresectable advanced gastric cancer
ChiCTR1800016138Phase 4Recruiting
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- Dec 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib, tegafur and oxaliplatin in gastric cancer (GC), sponsored by Yantai Yuhuangding Hospital. Primary endpoints: R0 resection rate and safety. Started Dec 2017; status: recruiting.
02
Drugs
Rivoceranibtegafuroxaliplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR1800016138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016138.